Global Hematological Cancers Market report 2016 - 1,234 Pipeline Products in Active Development in the Hematological Cancer Therapy Area - Research and Markets
Sep 26, 2016, 12:10 ET
DUBLIN, September 26, 2016 /PRNewswire/ --
Research and Markets has announced the addition of the "Frontier Pharma: Hematological Cancers - Highly Innovative Pipeline Continues Trend towards Targeted, Patient-Specific Therapies" drug pipelines to their offering.
This latest report states that there are currently 1,234 pipeline products in active development in the hematological cancer therapy area, and for each of the three key indications, the composition by stage of development is relatively similar, although leukemia and myeloma have more products in clinical development.
Of the three major indications within hematological cancer, namely leukemia, lymphoma and myeloma, leukemia has the largest pipeline, with 798 products in active development, while lymphoma has 552 and myeloma has 396, according to the report.
Leukemia has the most products in the hematological cancers pipeline, with 349 in clinical development and 446 in early-stage development, while three products had an undisclosed stage of development. In terms of individual stages, however, Preclinical is the largest across leukemia and lymphoma, while Phase II is the largest in myeloma. It is notable that Phase II also contains many products for leukemia and lymphoma, which is a promising trend for product development. The leukemia indication contains the most first-in-class products, with 195, while the lymphoma and myeloma pipelines contain 186 and 8 first-in-class products, respectively.
The report also states that considerable unmet needs remain in hematological cancer, with acute myeloid leukemia (AML) particularly ill-served, as there is a need for more efficacious targeted therapies across all patient subtypes. The treatment of AML is still limited to conventional DNA-targeted chemotherapy regimens, which achieve long-term survival rates of 25-50% in patients below the age of 60, and only 5-15% in older patients, indicating a clear need for more efficacious treatments.
This report provides analysis of the hematological cancers treatment pipeline, stratified by stage of development, molecule type and molecular target. It includes information on the current clinical and commercial landscape, and the composition of the hematological market in terms of dominant molecule types and targets, as well as highlighting current unmet needs.
Key Topics Covered:
1 Tables & Figures
2 Executive Summary
2.1 Significant Unmet Needs Persist in Hematological Cancer Market
2.2 Large Hematological Cancer Pipeline Displays Strong Degree of Innovation
2.3 Leuekmia Displays Most Pipeline Activity among Hematological Cancer Indications
3 The Case for Innovation in Hematological Cancers
3.1 Growing Number of Opportunities for Biologic Products
3.2 Diversification of Molecular Targets
3.3 Innovative First-in-Class Product Developments Remain Attractive
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation
3.5 Sustained Innovation
3.6 Report Guidance
4 Clinical and Commercial Landscape
4.1 Disease Overview
4.2 Epidemiology
4.3 Pathophysiology
4.4 Symptoms
4.5 Diagnosis
4.6 Prognosis and Survival
4.7 Treatment
4.8 Overview of Marketed Products
5 Assessment of Pipeline Product Innovation
5.1 Pipeline by Molecule Type, Phase and Therapeutic Target
5.2 Comparative Distribution of Programs between Hematological Cancer Market and Pipeline by Therapeutic Target Family
5.3 First-in-Class Pipeline Programs
6 Hematological Cancer Pathophysiology and Innovation Alignment
6.1 The Complexity of Signaling Networks in the Oncology
6.2 Signaling Pathways, Disease-Causing Mutations and First-in-Class Molecular Target Integration
6.3 First-in-Class Target Matrix Assessment
7 First-in-Class Target Evaluation
7.1 Pipeline Programs which Target Interleukin-7 Receptor
7.2 Pipeline Programs that Target Notch 2 and Notch 3
7.3 Pipeline Programs that Target Focal Adhesion Kinase
7.4 Pipeline Programs that Target Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1
7.5 Pipeline Programs that Target Interleukin-1 Receptor Accessory Protein
7.6 Pipeline Programs that Target HLA-DR
7.7 Pipeline Programs that Target L-Selectin
7.8 Pipeline Programs that Target Eukaryotic Translation Initiation Factor 4E
8 Strategic Consolidations
8.1 Industry-Wide First-in-Class Deals
8.2 Licensing Deals
8.3 Co-development Deals
8.4 First-in-Class Programs Not Involved in Licensing or Co-Development Deals
9 Appendix
For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/5zg42d/frontier_pharma
Media Contact:
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets